688139 海尔生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入652,079-5.36%2,328,6722,283,8332,280,8962,864,045
减:营业总成本581,5441.08%2,111,3501,941,8581,966,9372,293,396
    其中:营业成本342,016-3.88%1,239,1051,187,9151,172,3401,484,881
               财务费用2,497-141.44%(25,878)(47,254)(23,532)(20,279)
               资产减值损失206-125.12%(8,508)(2,756)(1,643)(5,410)
公允价值变动收益497126.14%(494)5,4692,056(7,007)
投资收益2,606-65.39%27,30923,79583,03374,721
    其中:对联营企业和合营企业的投资收益828-7.31%5,2427,6878,1738,963
营业利润83,932-33.67%266,343401,828438,401675,680
利润总额84,606-32.58%264,760401,957434,491675,336
减:所得税费用4,617-50.31%9,62820,94922,43363,362
净利润79,989-31.16%255,132381,008412,059611,974
减:非控股权益528-91.10%4,40114,3755,98511,183
股东净利润79,461-27.93%250,731366,633406,074600,791

市场价值指针
每股收益 (元) *0.250-28.57%0.8001.1601.2801.890
每股派息 (元) *----0.3300.4700.5150.450
每股净资产 (元) *14.0730.41%13.76213.74913.30612.645
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容